Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer

Background: This study compared the effects of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as 64Cu-chelating agents in newly developed prostate-specific membrane antigen (PSMA) target compounds, 64Cu-cudotadipep and 64Cu-cunotadipep, on pharmacokinetics. Methods: The in vitro stability of the chelators was evaluated using human and mouse serum. In vitro PSMA-binding affinity and cell uptake were compared using human 22Rv1 cells. To evaluate specific PSMA-expressing tumor-targeting efficiency, micro-positron emission tomography (mcroPET)/computed tomography (CT) and biodistribution analysis were performed using PSMA+ PC3-PIP and PSMA− PC3-flu tumor xenografts. Results: The serum stability of DOTA- or NOTA-conjugated 64Cu-cudotadipep and 64Cu-cunotadipep was >97%. The Ki value of the NOTA derivative, cunotadipep, in the in vitro affinity binding analysis was higher (2.17 ± 0.25 nM) than that of the DOTA derivative, cudotadipep (6.75 ± 0.42 nM). The cunotadipep exhibited a higher cellular uptake (6.02 ± 0.05%/1 × 106 cells) compared with the cudotadipep (2.93 ± 0.06%/1 × 106 cells). In the biodistribution analysis and microPET/CT imaging, the 64Cu-labeled NOTA derivative, 64Cu-cunotadipep, demonstrated a greater tumor uptake and lower liver uptake than the DOTA derivative. Conclusions: This study indicates that the PSMA-targeted 64Cu-cunotadipep can be applied in clinical practice owing to its high diagnostic power for prostate cancer.

[1]  Seunggyun Ha,et al.  Irreversible electroporation for prostate cancer using PSMA PET-CT , 2022, Prostate international.

[2]  S. Sreekumar,et al.  Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer , 2022, Pharmaceuticals.

[3]  C. Cutler,et al.  67Cu Production Capabilities: A Mini Review , 2022, Molecules.

[4]  T. Derlin,et al.  [18F]DCFPyL PET/CT for Imaging of Prostate Cancer. , 2022, Nuklearmedizin. Nuclear medicine.

[5]  Young Seok Kim,et al.  Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer , 2021, Cancer research and treatment.

[6]  Mi Hyun Kim,et al.  Improving Theranostic Gallium-68/Lutetium-177–Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer , 2021, Molecular Cancer Therapeutics.

[7]  Weiwei Tang,et al.  Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges , 2021, Frontiers in Cell and Developmental Biology.

[8]  K. Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018 , 2021, Cancer research and treatment.

[9]  Kyo-Chul Lee,et al.  The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer. , 2021, Cancer biotherapy & radiopharmaceuticals.

[10]  V. Tolmachev,et al.  Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer , 2020, Molecules.

[11]  Byung Il Kim,et al.  A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer , 2020, EJNMMI Research.

[12]  C. Buchpiguel,et al.  Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. , 2020, Radiographics : a review publication of the Radiological Society of North America, Inc.

[13]  Kyo-Chul Lee,et al.  18F‐labeled 1,2,3‐triazole‐linked Glu‐urea‐Lys‐based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer , 2020, The Prostate.

[14]  T. Holland-Letz,et al.  Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence , 2020, The Journal of Nuclear Medicine.

[15]  Byung Il Kim,et al.  A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  U. Tateishi.  Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer , 2020, Japanese journal of clinical oncology.

[17]  A. Villers,et al.  Imaging for Metastasis in Prostate Cancer: A Review of the Literature , 2020, Frontiers in Oncology.

[18]  U. Haberkorn,et al.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients , 2019, The Journal of Nuclear Medicine.

[19]  Z. Savin,et al.  Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard , 2019, The Journal of Nuclear Medicine.

[20]  Chun-hua Yang,et al.  Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer. , 2019, Discovery medicine.

[21]  Zhenyuan Miao,et al.  Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment. , 2019, European journal of medicinal chemistry.

[22]  Youngho Seo,et al.  Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies , 2019, The Journal of Nuclear Medicine.

[23]  Marie Brandt,et al.  An Overview of PET Radiochemistry, Part 2: Radiometals , 2018, The Journal of Nuclear Medicine.

[24]  G. Cheon,et al.  Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges , 2018, Korean journal of radiology.

[25]  K. Rahbar,et al.  PSMA Theranostics: Current Status and Future Directions , 2018, Molecular imaging.

[26]  H. Klingler,et al.  Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer , 2018, Advances in Therapy.

[27]  Wolfgang A Weber,et al.  Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview , 2017, The Journal of Nuclear Medicine.

[28]  A. Salonia,et al.  Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. , 2017, Urology.

[29]  M. Pomper,et al.  Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL. , 2017, PET clinics.

[30]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[31]  Xing Yang,et al.  64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model , 2017, Oncotarget.

[32]  Marcia M. Miller,et al.  Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer , 2017, The Journal of Nuclear Medicine.

[33]  B. Hadaschik,et al.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  H. Klingler,et al.  64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. , 2016, Cancer biotherapy & radiopharmaceuticals.

[35]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[36]  M. Pomper,et al.  64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer , 2014, Journal of medicinal chemistry.

[37]  Yin Zhang,et al.  Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA , 2011, PloS one.

[38]  S. Figueroa,et al.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues , 2007, Proceedings of the National Academy of Sciences.

[39]  S. Achilefu,et al.  Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator , 2004, Clinical Cancer Research.

[40]  Weijun Niu,et al.  Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. , 2004, Journal of medicinal chemistry.

[41]  H. Cheng,et al.  The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. , 2001, Journal of pharmacological and toxicological methods.

[42]  B. Kurland,et al.  Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer , 2015, Molecular Imaging and Biology.